Almirall SA · BME:ALM

Almirall SA — CITI Healthcare Conference 2011

19 slides from Almirall SA's conference presentation, Mar 2, 2011

  1. Slide 1: CITI Healthcare Conference

    Slide 1: CITI Healthcare Conference

    CITI Healthcare Conference New York, March 2nd, 2011

  2. Slide 2: Almirall at a glance

    Slide 2: Almirall at a glance

    Almirall at a glance A . (4 Almirall Solutions with you in mind

  3. Slide 3: Highlights 2010

    Slide 3: Highlights 2010

    Highlights 2010 Setting the basis for sustainable long-term growth Results in line with guidance Significant Significant pipeline pipeline progression progression Focused Focused cost cost optimisation optimisation • Phase III completion of aclidinium • SG&A reduction of 6%. bromide monotherapy and

  4. Slide 4: Summary – 2010 Financial Results

    Slide 4: Summary – 2010 Financial Results

    Summary – 2010 Financial Results • Sales (-4,7%) and Normalized Net Income (-5,9%) within guidance. • Strong operational savings in 2010 (SG&A: -6,0%). • Significant R&D investment to progress pipeline (+ 19,8%). • Net Debt remains low at 0,10xEBITDA 2010 and provides strong strategic flexibility. •

  5. Slide 5: Strategic axes to foster long term growth

    Slide 5: Strategic axes to foster long term growth

    Strategic axes to foster long term growth 2007 2010 1 Growing internationally • % of sales 34% 44% 2 Leveraging own R&D • Projects in clinical development stage 8 12 • Projects in phase III / registration 5 7 3 Maintaining leadership in Spain • Largest Spanish pharma company 9 9 • Ranked among top 5

  6. Slide 6: Our pipeline

    Slide 6: Our pipeline

    Our pipeline R&D highlights 6 Dr Per Olof Andersson, CSO

  7. Slide 7: R&D 2010 highlights

    Slide 7: R&D 2010 highlights

    R&D 2010 highlights • Positive phase III completion of aclidinium bromide monotherapy and linaclotide. Filings expected in 2011. • Positive phase IIb completion of aclidinium bromide + formoterol. Phase III due to start in 2011. • Reinforcing our respiratory franchise with a new MABA* candidate in p

  8. Slide 8: Newsflow during 2011

    Slide 8: Newsflow during 2011

    Newsflow during 2011 1st 1st Half Half 2011 2011 2nd 2nd Half Half 2011 2011 LAS100977 + ICS New Phase II studies Further data on Further data on AB results at ATS AB results at ERS R&D R&D AB + formoterol (BID) Phase III initiation LAS41007 LAS41007 Phase Phase III III completion completion LAS4100

  9. Slide 9: Three compounds entering phase III

    Slide 9: Three compounds entering phase III

    Three compounds entering phase III Indication Start date Compound AB AB ++ COPD H2 2011 LAMA + LABA formoterol formoterol Tetrahydro- Sativex®® Sativex Oncological pain Q4 2010 cannabinol / cannabidiol Non-melanoma LAS41007 LAS41007 Q4 2010 Undisclosed skin cancer AB: aclidinium bromide | LAMA: long

  10. Slide 10: Two major filings expected in 2011: aclidinium bromide

    Slide 10: Two major filings expected in 2011: aclidinium bromide

    Two major filings expected in 2011: aclidinium bromide • Positively completed phase III showed competitive efficacy and good tolerability. • Well positioned to be the 2nd LAMA in the COPD market. • Convenient Genuair® MDPI device. • Sizable and growing global COPD market of € 9bn with significant un

  11. Slide 11: Two major filings expected in 2011: linaclotide

    Slide 11: Two major filings expected in 2011: linaclotide

    Two major filings expected in 2011: linaclotide A first-in-class treatment developed for IBS-C • IBS is a functional gastrointestinal disorder with abdominal pain and altered bowel habits. • No product approved by EMA so far in this indication. • In H2 2010, positive topline results from two pivotal

  12. Slide 12: Building a strong respiratory franchise around the Genuair device

    Slide 12: Building a strong respiratory franchise around the Genuair device

    Building a strong respiratory franchise around the Genuair® device • Aclidinium bromide ready to file in the US and EU. • The aclidinium + formoterol combination progressing to phase III for US and EU. • The Once Daily LABA/steroid combination progressing in phase II. • Preparing for MABA* to enter

  13. Slide 13: Building the dermatology franchise

    Slide 13: Building the dermatology franchise

    Building the dermatology franchise • Actikerall®(LAS41005) for non-melanoma skin cancer approaching regulatory feedback. • LAS41002 for skin inflammation approaching regulatory feedback. • LAS41007 for non-melanoma skin cancer: phase III expected to be completed in second half 2011. • LAS41003 (infe

  14. Slide 14: A pipeline with significant upside (I)

    Slide 14: A pipeline with significant upside (I)

    Auto-immune A pipeline with significant upside (I) Dermatology Gastrointestinal Respiratory Expected filing Preclinical Ph I Ph II Ph III Registration date Approved in Spain Multiple Multiple Sclerosis Sclerosis Spasticity Spasticity Sativex® (CB agonist) MRP Ongoing Actikerall® Non-melanoma Non-mel

  15. Slide 15: A pipeline with significant upside (II)

    Slide 15: A pipeline with significant upside (II)

    Auto-immune A pipeline with significant upside (II) Dermatology Respiratory Expected filing Preclinical Ph I Ph II Ph III Registration date LAS100977 + ICS (OD LABA + ICS) Asthma Asthma // COPD COPD >2014 2013 LAS41003 (combination) Infected Infected eczema eczema LAS41004 (combination) Psoriasis Ps

  16. Slide 16: Key deliverables in 2011

    Slide 16: Key deliverables in 2011

    Key deliverables in 2011 R&D highlights 16 Dr Per Olof Andersson, CSO

  17. Slide 17: Projected key deliverables in the next 12 months

    Slide 17: Projected key deliverables in the next 12 months

    Projected key deliverables in the next 12 months Operations Corporate Development R&D and Regulatory • Launch of Sativex® in • Partnering of aclidinium • Two major filings: Spain, Denmark, in Europe and other aclidinium and linaclotide. Germany and Sweden. selected geographies. • Aclidinium + formot

  18. Slide 18: For further information, please contact

    Slide 18: For further information, please contact

    For further information, please contact: Jordi Molina, Head of Investor Relations Ph. +34 93 291 3087 jordi.molina@almirall.com Or visit our website: www.almirall.com 18

  19. Slide 19: Almirall – Solutions with you in mind

    Slide 19: Almirall – Solutions with you in mind

    Z . (4% Almirall Solutions with you in mind

Source: Internet Archive copy of almirall.com

More decks from Almirall SA

All 39 Almirall SA decks